Jiuzhitang Meike

Jiuzhitang Meike is a Beijing-based biotechnology company focused on the research, development, and large-scale production of mesenchymal stem cell (MSC) therapies. Established as a strategic subsidiary of the historic pharmaceutical firm Jiuzhitang, the company operates a high-standard cGMP facility for the manufacture of allogeneic bone marrow-derived MSCs. Their core technology is licensed from the American company Stemedica Cell Technologies, enabling the production of stem cells under low-oxygen conditions to enhance potency and stability. Jiuzhitang Meike's clinical pipeline primarily targets high-unmet-need areas such as ischemic stroke, chronic obstructive pulmonary disease, and knee osteoarthritis. The company represents a significant effort to integrate modern regenerative medicine into the broader portfolio of one of China's oldest healthcare brands.